Some participants in early studies experienced slight increases in heart rate or mild rhythm disturbances
Diabetes Care 33(2):428433 Eguchi Y, Kitajima Y, Hyogo H, Takahashi H, Kojima M, Ono M et al (2015) Pilot study of liraglutide effects in non-alcoholic steatohepatitis and non-alcoholic fatty liver disease with glucose intolerance in Japanese patients (LEAN-J)
No hidden fees, no surprise costs
What a GLP-1 reset actually means The term GLP-1 reset gets thrown around loosely in online communities
In addition to weight reduction, the Phase 2 trial reported improvements in several cardiometabolic markers, including: Reductions in waist circumference Improvements in blood pressure Favourable changes in lipid profiles Reductions in fasting glucose and insulin resistance Increases in heart rate were also observed, consistent with findings seen with other incretin-based therapies These findings suggest that retatrutide may offer broader metabolic benefits beyond weight loss alone, which is particularly relevant for patients with obesity-related comorbidities such as type 2 diabetes, metabolic dysfunction-associated steatotic liver disease (MASLD), or elevated cardiovascular risk
